Skip to content

Add anything here or just remove it...

Home
About
Imatinib for COVID-19
News
Exvastat
Contact

Design

Another Print Package

Design

FL3 Print Package

Design

Awesome Pencil Poster

Design

Portfolio typography

Design

Flatsome Poster Print

Design

Magazine

Design

Home
About
Imatinib for COVID-19
News
Exvastat
Contact

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101005142.

This Joint Undertaking receives support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.

IMPENTRI IMI2Follow

catch our colleague, Dr Imke Bartelink presenting this morning at the #EACPT2022 on “Pharmacokinetics and Pharmacodynamics for Optimal Drug Repurposing of Imatinib from Cancer to COVID-19”

Reply on Twitter 1541688176728842241 Retweet on Twitter 1541688176728842241 Like on Twitter 15416881767288422412 Twitter 1541688176728842241

Have a look at @InnoRadarEU's page for the #EUfunded #innovation: 'Evaluation of the safety and efficacy of intravenous imatinib (Impentri™) for the treatment of patients with moderate to severe Acute Respiratory Distress Syndrome, caused by COVID'. https://www.innoradar.eu/innovation/41910

Reply on Twitter 1539212189696933891 Retweet on Twitter 1539212189696933891 Like on Twitter 15392121896969338912 Twitter 1539212189696933891

Check out the presentations this morning, from the clinical teams from AMC and VUmc, Amsterdam, who are presenting their results of the clinical trial of oral imatinib for the treatment of hospitalized COVID-19 patients. #ATS2022

Reply on Twitter 1526934267179180032 Retweet on Twitter 1526934267179180032 Like on Twitter 15269342671791800321 Twitter 1526934267179180032

Copyright 2022 © Exvastat Ltd

Home
About
Imatinib for COVID-19
News
Exvastat
Contact